Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Aims to achieve CDMO sales of US$ 400 million by 2028
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
ALS patients experience neuroinflammation and rapid neurodegeneration
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Subscribe To Our Newsletter & Stay Updated
